Literature DB >> 3498585

Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody.

R Burger1, A Bader, M Kirschfink, U Rother, L Schrod, I Wörner, G Zilow.   

Abstract

The C3 fragment C3a belongs to the anaphylatoxins. It has immune regulatory activity and contributes to the pathogenesis of the adult respiratory distress syndrome (ARDS). The low molecular weight (9 kD) of C3a complicates the production of antibodies to C3a. We obtained a monoclonal antibody (designated H13) to human C3a. It reacts with C3a or C3a-desArg and with native C3 but not with C5 or C5a. In immunoblot analysis it reacts with the alpha- but not with beta-chain of C3 and binds to a protein with a mol. wt of about 10 kD present in zymosan-activated sera which is only marginally detectable in nonactivated serum and absent in plasma. H13 crossreacts with the analogous proteins of rabbit, guinea pig and sheep. H13 has the capacity to bind 125I-radiolabelled C3a efficiently but fails totally to react with 125I-C5a or with other C3 alpha-chain fragments. H13 blocks C3a functional activity. It markedly inhibits C3a-induced 3H-serotonin release from platelets in vitro and similarly inhibits the C3a-induced extravasation of Evans blue into the skin in vivo. H13 does not interfere with the haemolytic activity of C3. An ELISA system was established using H13 which permits quantification of C3a in sera of polytrauma patients. The antibody H13 should facilitate further functional analysis of C3a in experimental systems. It should be useful for quantification of C3a in diagnostic assays and also for application in immunopathology.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498585      PMCID: PMC1542768     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

2.  Leucocyte mobilizing factor: a new biological activity derived from the third component of complement.

Authors:  K Rother
Journal:  Eur J Immunol       Date:  1972-12       Impact factor: 5.532

3.  Identification of functionally relevant determinants on the complement component C3 with monoclonal antibodies.

Authors:  R Burger; U Deubel; U Hadding; D Bitter-Suermann
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

Review 4.  The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a.

Authors:  T E Hugli
Journal:  Crit Rev Immunol       Date:  1981-02       Impact factor: 2.214

Review 5.  Adult respiratory-distress syndrome: changing concepts of lung injury and repair.

Authors:  J E Rinaldo; R M Rogers
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

6.  Platelet-serotonin release by C3a and C5a: two independent pathways of activation.

Authors:  S Meuer; U Ecker; U Hadding; D Bitter-Suermann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

7.  Isolation of three separate anaphylatoxins from complement-activated human serum.

Authors:  T E Hugli; C Gerard; M Kawahara; M E Scheetz; R Barton; S Briggs; G Koppel; S Russell
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

8.  Large scale isolation of functionally active components of the human complement system.

Authors:  C H Hammer; G H Wirtz; L Renfer; H D Gresham; B F Tack
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

9.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

10.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more
  7 in total

1.  Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.

Authors:  E Jelezarova; A Vogt; H U Lutz
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

2.  Structural transitions of complement component C3 and its activation products.

Authors:  Noritaka Nishida; Thomas Walz; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

3.  Mechanisms of C5a and C3a complement fragment-induced [Ca2+]i signaling in mouse microglia.

Authors:  T Möller; C Nolte; R Burger; A Verkhratsky; H Kettenmann
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

4.  Monoclonal antibodies for clinical applications. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1988-12       Impact factor: 2.926

5.  Neutrophils Induce Astroglial Differentiation and Migration of Human Neural Stem Cells via C1q and C3a Synthesis.

Authors:  Mitra J Hooshmand; Hal X Nguyen; Katja M Piltti; Francisca Benavente; Samuel Hong; Lisa Flanagan; Nobuko Uchida; Brian J Cummings; Aileen J Anderson
Journal:  J Immunol       Date:  2017-07-07       Impact factor: 5.422

6.  Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma.

Authors:  Michael L Manning; Simon A Williams; Christine A Jelinek; Maya B Kostova; Samuel R Denmeade
Journal:  J Immunol       Date:  2013-02-11       Impact factor: 5.422

7.  Influence of Absorbable Calcium Sulfate-Based Bone Substitute Materials on Human Haemostasis-In Vitro Biological Behavior of Antibiotic Loaded Implants.

Authors:  Dominik Pförringer; Norbert Harrasser; Marc Beirer; Moritz Crönlein; Axel Stemberger; Martijn van Griensven; Martin Lucke; Rainer Burgkart; Andreas Obermeier
Journal:  Materials (Basel)       Date:  2018-06-01       Impact factor: 3.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.